Early diagnosis of Alzheimer's disease (AD) is needed to initiate symptomatic treatment with
acetylcholinesterase inhibitors, and will be of even greater significance if drugs aimed at …

Developing effective treatments for neurodegenerative diseases is one of the greatest
medical challenges of the 21st century. Although many of these clinical entities have been …

Primary progressive aphasia (PPA) is a disorder of declining language that is a frequent
presentation of neurodegenerative diseases such as frontotemporal lobar degeneration …

The aim of this international guideline on dementia was to present a peer‐reviewed
evidence‐based statement for the guidance of practice for clinical neurologists, geriatricians …

Background The cerebrospinal fluid (CSF) biomarkers amyloid β (Aβ)‐42, total‐tau (T‐tau),
and phosphorylated‐tau (P‐tau) demonstrate good diagnostic accuracy for Alzheimer's …

The introduction of acetylcholine esterase (AChE) inhibitors as a symptomatic treatment of
Alzheimer's disease (AD) has made patients seek medical advice at an earlier stage of the …

Objective Cerebrospinal fluid (CSF) neurofilament light chain (NfL) concentration is elevated
in neurological disorders, including frontotemporal degeneration (FTD). We investigated the …

Background: To improve ante mortem diagnostic accuracy of Alzheimer disease (AD),
measurement of the biomarkers amyloid-β (1–42)(Aβ42), total tau (Tau), and tau …

Progressive cognitive decline in combination with a cerebrospinal fluid biomarker pattern of
low levels of amyloid-β1-42 and high levels of total tau and phosphorylated tau is typical of …

Background Tau and β-amyloid (Aβ) are proposed diagnostic biomarkers for Alzheimer
disease (AD). Previous studies report their relationship to clinical diagnoses of AD and other …